Madrigal Pharmaceuticals hits profitability as Rezdiffra tops $1bn

Rezdiffra posted $431m in Q3 2026 net sales, up 50% year-on-year, as Madrigal recorded its first profitable quarter and launched a new Phase

A bright, clean medical examination room features a large, modern white and grey medical imaging machine with an overhead arm and a long patient table, alongside a white floating shelf holding two small potted plants.

Madrigal Pharmaceuticals has reported its first quarter of profitability, posting net income of $55.4 million for the three months ended 30 September 2026 as demand for its liver-disease treatment Rezdiffra (resmetirom) continued to accelerate. Third-quarter net sales reached $431.3 million, a 50% increase on the same period a year earlier, while year-to-date revenues crossed $1.1 billion, the conventional threshold for blockbuster status.

The Pennsylvania-based company said more than 55,850 patients were on Rezdiffra as of 30 September, almost double the figure recorded in the equivalent quarter of 2025. Madrigal described the addressable US market for moderate-to-advanced MASH fibrosis (stages F2 to F3) as now comprising more than 530,000 patients, with its own projections pointing to growth of over 30% by year-end 2026.

Expanding the clinical programme

Alongside the financial results, Madrigal announced a new Phase 3 outcomes trial, MAESTRO-CSPH, targeting compensated MASH cirrhosis (F4c). The event-driven study is designed to enrol more than 2,000 patients, with enrolment enriched for clinically significant portal hypertension. Madrigal said it expects to initiate the trial in the first half of 2027, subject to regulatory discussions, and that the study will also support validation of non-invasive biomarkers for resmetirom.

The move is strategically significant. While the existing MAESTRO-NASH OUTCOMES study, which is due to report data in late 2027, addresses the same F4c population, MAESTRO-CSPH is designed to extend Madrigal's clinical dataset and reinforce its position ahead of any competitors entering the cirrhosis space. Chief executive Bill Sibold said the company's objective in F4c was to "be first and best," framing the new trial as an extension of competitive advantage rather than a redundant effort.

A secondary analysis of the Phase 3 MAESTRO-NASH trial, recently published in the Journal of Hepatology, also showed that resmetirom improved liver histology and MRI-PDFF scores across patients carrying common MASH-associated genetic variants, including PNPLA3, TM6SF2 and HSD17B13. The finding is relevant because genetic risk variants complicate patient stratification in MASH; evidence of consistent efficacy across variant groups strengthens the drug's candidacy as a broad foundational therapy.

Market context and competitive landscape

Rezdiffra remains the only approved therapy for MASH with moderate-to-advanced fibrosis, having received FDA approval in March 2024 and European Commission authorisation shortly after. Competing programmes from companies including Novo Nordisk, Eli Lilly and AstraZeneca are at various stages of clinical development, primarily leveraging GLP-1 receptor agonist mechanisms. None has reached approval specifically for MASH fibrosis improvement as of this reporting date, leaving Madrigal with a window of market exclusivity it is visibly working to extend through the MAESTRO-CSPH programme.

Operating expenses fell to $375.3 million in the quarter from $401.2 million a year earlier, though the prior period included a one-off $117.3 million business development charge that inflates the comparison. Underlying selling, general and administrative costs rose to $265.7 million, partly reflecting the expansion of an endocrinology field force and a direct-to-consumer marketing campaign launched in late 2025. Cash and marketable securities stood at $961.8 million at the quarter end, down marginally from $988.6 million at the close of 2025.

The company also announced that John C. Reed, executive vice-president of research and development at Johnson and Johnson, joined its board in August. Reed previously held senior R&D roles at Sanofi and Roche. Madrigal will present 18 abstracts at the AASLD Liver Meeting in Denver from 5 to 9 November, including 13 based on real-world evidence covering a dataset of nearly 12,000 patients.